Kuros Biosciences AG
SIX:KURN

Watchlist Manager
Kuros Biosciences AG Logo
Kuros Biosciences AG
SIX:KURN
Watchlist
Price: 20.1 CHF -3.13% Market Closed
Market Cap: 755.2m CHF
Have any thoughts about
Kuros Biosciences AG?
Write Note

P/FCFE
Price to FCFE

-185.2
Current
-10.3
Median
23.4
Industry
Lower than median
Lower than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE
-185.2
=
Market Cap
739m CHF
/
FCFE
-4m CHF
All Countries
Close
Market Cap P/FCFE
CH
Kuros Biosciences AG
SIX:KURN
739m CHF -185.2
FR
Pharnext SCA
OTC:PNEXF
6T USD -3 224 032.7
US
Abbvie Inc
NYSE:ABBV
310.3B USD 12.4
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 23.9
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 11.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD -77.4
US
Epizyme Inc
F:EPE
94.1B EUR -425.6
AU
CSL Ltd
ASX:CSL
133.7B AUD 75.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 23.3
US
Seagen Inc
F:SGT
39.3B EUR -58.5
NL
argenx SE
XBRU:ARGX
36.2B EUR -114
 
CH
Kuros Biosciences AG
SIX:KURN
Average P/FCFE: 29.4
Negative Multiple: -185.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -3 224 032.7
US
Abbvie Inc
NYSE:ABBV
12.4
US
Amgen Inc
NASDAQ:AMGN
23.9
US
Gilead Sciences Inc
NASDAQ:GILD
11.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -77.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -425.6
AU
CSL Ltd
ASX:CSL
75.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
23.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5
NL
argenx SE
XBRU:ARGX
Negative Multiple: -114

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A

See Also

Discover More